A Phase 3 Trial of Semagacestat for Treatment of Alzheimer's Disease

20131,201 citationsJournal Article

Authors

Rachelle S. Doody · Baylor College of Medicine

Rema Raman · University of California, San Diego

Martin R. Farlow · Indiana University

Takeshi Iwatsubo · The University of Tokyo

Bruno Vellas · Hôpital de La Grave

Steven Joffe · Boston Children's Hospital

Karl Kieburtz ·

Abstract

As compared with placebo, semagacestat did not improve cognitive status, and patients receiving the higher dose had significant worsening of functional ability. Semagacestat was associated with more adverse events, including skin cancers and infections. (Funded by Eli Lilly; ClinicalTrials.gov number, NCT00594568.)

Topics & Keywords

Alzheimer's disease research and treatments Cholinesterase and Neurodegenerative Diseases Nuclear Receptors and Signaling

UN Sustainable Development Goals

Good health and well-being

Publication Details

Published in: New England Journal of Medicine

Volume 369, Issue 4, pp. 341-350

DOI: 10.1056/nejmoa1210951

Field-Weighted Citation Impact: 51.36